Clinical Oncology NewsExpert Commentary: The Future of IbrutinibClinical Oncology NewsIn addition, the US cooperative groups led by the Alliance for Clinical Trials in Oncology are currently planning a randomized study of initial therapy in older patie…
|
Merck, Samsung JV Team Up On Biosimilar Meds
Manufacturing.net The company, based in Whitehouse Station, N.J., has said it’s developing an experimental biosimilar version of rituximab, an antibody-based biologic drug sold under brand names including Rituxan. Samsung Bioepis is a joint venture between Korea’s … |
 TIME |
Bitter Pill: Why Medical Bills Are Killing Us
TIME Recchi was charged $13,702 for “1 RITUXIMAB INJ 660 MG.” That’s an injection of 660 mg of a cancer wonder drug called Rituxan. The average price paid by all hospitals for this dose is about $4,000, but MD Anderson probably gets a volume discount that … |
|
Linfoma non-Hodgkin. Bendamustina più rituximab meglio della terapia standard
Quotidiano Sanità 20 FEB – L’associazione bendamustina più rituximab (B-R) in pazienti con linfoma non-Hodgkin indolente e mantellare raddoppia la sopravvivenza libera da progressione di malattia (PFS), rispetto al trattamento standard CHOP (ciclofosfamide, doxorubicina … |
|
Mundipharma’s bendamustine plus rituximab doubles PFS in non-Hodgkin …
The Pharma Letter Results from the StiL NHL-1 study published in the Lancet today (February 20) show that a first-line treatment regimen of bendamustine (marketed under the trade name Levact by privately-held Swiss drugmaker Mundipharma) plus rituximab (B-R) doubles … |
|
For further information please contact: Lara Dow,
BörseGo.de Auch wenn beim G20-Treffen am Wochenende die Gefahr eines drohenden „Währungskrieges“ bewusst kleingeredet wurde, befürchten Experten, das nach Japan auch andere Länder dazu übergehen könnten, ihre Währungen abzuwerten, um sich dadurch … |
– Treatment with bendamustine plus rituximab (BR) doubles progression free …EIN News (press release)Bendamustine is currently licensed for use after rituximab, an application has been made on the basis of this data for first line use. Results from th…
|
Phase 3 Data Published in The Lancet Show Bendamustine (Levact®) Plus …
SYS-CON Media (press release) Results from the StiL NHL-1 study published in the Lancet today show that a first-line treatment regimen of bendamustine plus rituximab (B-R) doubles progression-free survival (PFS) compared with the most often used treatment CHOP plus rituximab … |
MECHELEN, Belgium, February 20, 2013 /PRNewswire/ –PR Newswire UK (press release)Bendamustine is currently licensed for use after rituximab, an application has been made on the basis of this data for first line use. Results from the StiL NHL-1 study p…
Zortress Indication Expanded for Liver Transplant PatientsMonthly Prescribing ReferenceZortress is currently indicated for organ rejection prophylaxis in renal transplant patients with low-moderate immunologic risk, in combination with basiliximab indu…